APOB and hyperlipidemia: Evolocumab/alirocumab and mipomersen inhibit key players (PCSK9 and apoB) in lipid transport helping to lower plasma LDL-C levels.38 The Zheng et al33 MR study showed a negative effect of reduced PCSK9 levels on high cholesterol in the UK Biobank, while in 25 RCT studies drug-induced abrogation of PCSK9 activity led to positive outcomes in the treatment of hyperlipidaemia, hypercholesterolaemia and dyslipidaemias in general.